MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences DSO Ratio 2011-2026 | ANIX
Annual DSO Ratio Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 275 | - | - | - | 97.1 | - | - | - | - | 39.8 | 164 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 275 | 39.8 | 144 |
Quarterly DSO Ratio Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 55.6 | 4.18 | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 24.3 | 12.1 | - | 25.2 | 38.6 | - | - | 27.8 | 27.8 | - | - | - | - | - | 0.22 | - | - | - | - | 15.9 | 30.7 | 16.5 | 3.75 K | - | - | - | 0.71 | 912 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.75 K | 0.22 | 310 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
63.8 | $ 114.25 | -1.07 % | $ 34.7 B |  USA |
|
Biodesix
BDSX
|
41.7 | $ 15.55 | 3.19 % | $ 2.02 B | USA |
 |
Biomerica
BMRA
|
57.7 | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
63.7 | $ 1.2 | -0.03 % | $ 6.53 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
31.7 | $ 16.5 | 1.85 % | $ 178 M |  China |
 |
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 18.32 | 0.05 % | $ 976 M | USA |
 |
Co-Diagnostics
CODX
|
94.7 | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 168.44 | -3.13 % | $ 8.35 B | USA |
 |
Castle Biosciences
CSTL
|
49.2 | $ 24.85 | 0.04 % | $ 690 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 197.89 | 0.37 % | $ 22 B | USA |
 |
Danaher Corporation
DHR
|
55.3 | $ 190.62 | -0.26 % | $ 136 B | USA |
 |
DexCom
DXCM
|
87 | $ 62.7 | 0.76 % | $ 24.5 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 16.8 | -0.15 % | $ 508 M | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
46.1 | $ 92.35 | -1.58 % | $ 11.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | China |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 110.38 | -3.34 % | $ 9.1 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
66.9 | $ 1.96 | 5.82 % | $ 8.67 M | USA |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Illumina
ILMN
|
61.3 | $ 127.63 | 0.2 % | $ 20.3 B | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 168.24 | -2.9 % | $ 28.9 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 274.94 | 0.41 % | $ 22.9 B | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
80.5 | $ 76.0 | -0.14 % | $ 5.13 B | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 485.89 | -2.5 % | $ 14 B | USA |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 258.2 | -0.3 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.84 | 1.79 % | $ 448 M | USA |
 |
ENDRA Life Sciences
NDRA
|
7.11 | $ 4.69 | - | $ 3.69 M | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 8.06 | 0.75 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
66.6 | $ 9.42 | 0.11 % | $ 2.04 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.35 | 1.11 % | $ 388 M | USA |
 |
Natera
NTRA
|
81.5 | $ 207.01 | -0.46 % | $ 20.4 B | USA |
 |
Pacific Biosciences of California
PACB
|
71.8 | $ 1.36 | 1.49 % | $ 408 M | USA |
 |
Precipio
PRPO
|
21.1 | $ 25.23 | -1.29 % | $ 40.5 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 6.63 | 0.76 % | $ 393 M | USA |
 |
RadNet
RDNT
|
34.5 | $ 55.12 | 0.6 % | $ 4.14 B | USA |